Phase II Trial of Docetaxel Plus Oxaliplatin (DOCOX) With or Without Cetuximab in Patients With Metastatic Gastric and/or Gastroesophageal Junction Adenocarcinoma
Latest Information Update: 01 Nov 2019
Price :
$35 *
At a glance
- Drugs Cetuximab (Primary) ; Docetaxel; Oxaliplatin
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 07 Jun 2011 One-year results presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
- 28 Apr 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 03 Jul 2009 Planned end date changed to 1 Sep 2011.